Skip to main content
Premium Trial:

Request an Annual Quote

William Blair Initiates Coverage of Bruker with Outperform Rating

NEW YORK (GenomeWeb News) – William Blair initiated coverage of Bruker on Wednesday with an Outperform rating and a Core Growth company profile.

Analyst Amanda Murphy estimated 2011 EPS at $.89 on $1.63 billion in revenues, and 2012 EPS at $1.05 on $1.77 billion in revenues.

In a research note, Murphy cited Bruker's spending on R&D, which she said is higher than its peers on a percentage-of-revenue basis, resulting in strong brand reputation and a "robust" IP portfolio.

She added that the company is "one of the most well-diversified companies on our coverage list" with about 3 percent to 4 percent of total revenues derived from National Institutes of Health funding, and total government funding comprising around 9 percent of company-wide revenues. Future growth opportunities include further penetration into the applied markets and operating margin leverage, Murphy said.

The Scan

Panel Recommends Pfizer-BioNTech Vaccine for Kids

CNN reports that the US Food and Drug Administration advisory panel has voted in favor of authorizing the Pfizer-BioNTech SARS-CoV-2 vaccine for children between 5 and 11 years old.

Sharing How to Make It

Merck had granted a royalty-free license for its COVID-19 treatment to the Medicines Patent Pool, according to the New York Times.

Bring it Back In

Bloomberg reports that a genetic analysis has tied a cluster of melioidosis cases in the US to a now-recalled aromatherapy spray.

Nucleic Acids Research Papers on SomaMutDB, VThunter, SCovid Databases

In Nucleic Acids Research this week: database of somatic mutations in normal tissue, viral receptor-related expression signatures, and more.